Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.
Conditions: Relapsed Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma Intervention: Drug: Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy (R-BAC, Rituximab - Bendamustine, Ara-C)) Sponsor: Fondazione Italiana Linfomi ONLUS Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2022 Category: Research Source Type: clinical trials
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Conditions: DLBCL; Diffuse Large B-Cell Lymphoma Interventions: Biological: Zilovertamab vedotin; Biological: Rituximab; Drug: Gemcitabine; Drug: Oxaliplatin; Drug: Bendamustine Sponsor: Merck Sharp & Dohme Corp. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 1, 2021 Category: Research Source Type: clinical trials
